Esperion Launches New Scientific Website
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Morgan Stanley Opens Catalyst Driven Idea on Esperion Therapeutics (ESPR)
February 27, 2023 4:21 PM ESTMorgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $9.00 price target on Esperion Therapeutics (NASDAQ: ESPR)
The analyst comments "What is the catalyst? Data from Esperion's CLEAR outcomes study for LDLlowering drug Nexletol (bempedoic acid) in 14,000+ statin intolerant patients at high risk for cardiovascular disease will be presented in a... More



